Diabetes screening may not be cost-effective

	Tweet

Diabetes screening may not be cost-effective unless treatment is highly effective.

“The cost-effectiveness of screening for diabetes is unknown but has been modeled previously. None of these models has taken account of uncertainty. We aimed to describe these uncertainties in a model where the outcome was CHD risk,” scientists in England report.

C. Glumer and colleagues working with Elsie Widdowson Laboratories explained, “Our model used population data from the Danish Inter99 study, and simulations were run in a theoretical population of 1,000,000 individuals. CHD risk was estimated using the U.K.

Prospective Diabetes Study (UKPDS) risk engine, and risk reduction from published randomised clinical trials. Probabilistic sensitivity analysis was used to provide confidence intervals for modeled outputs. Uncertain parameter values were independently simulated from distributions derived from existing literature and deterministic sensitivity analysis performed using multiple model runs under different strategy choices and using extreme parameter estimates.

The researchers determined, “In the least conservative model (low costs and multiplicative risk reduction for combined treatments), the 95% confidence interval of the incremental cost-effectiveness ratio varied from UKP 23,300-82,000. The major contributors to this uncertainty were treatment risk reduction model parameters: the risk reduction for hypertension treatment and UKPDS risk model intercept. Overall cost-effectiveness ratio was not sensitive to decisions about which groups to screen, nor the costs of screening or treatment.

It was strongly affected by assumptions about how treatments combine to reduce risk.”

“Our model suggests,” concluded the authors, “that there is considerable uncertainty about whether or not screening for diabetes would be cost-effective. The most important but uncertain parameter is the effect of treatment. In addition to directly influencing current policy decisions, health care modeling can identify important unknown or uncertain parameters that may be the target of future research.”

Glumer and colleagues published their study in Diabetologia (What determines the cost-effectiveness of diabetes screening? Diabetologia, 2006;49(7):1536-1544).

For more information, contact N.J. Wareham, Medical Research Council, Epidemiology Unit, Elsie Widdowson Laboratories, 120 Fulbourn Rd., Cambridge CB1 9NL, England.

Publisher contact information for the journal Diabetologia is: Springer, 233 Spring Street, New York, NY 10013, USA.

RELATED STORIES:
Phone contact with nurses linked with better outcomes for women with gestational diabetes   Death rate drops among Americans with diabetes -CDC   Correct treatment of common diabetic foot infections can reduce amputations   “Pre-diabetes,” diabetes rising among U.S. teens   Experimental bariatric surgery controls blood sugar in rats with diabetes   53 millions Americans might develop diabetes by 2025   New inflammation hormone link may pave way to study new drugs for type 2 diabetes   Diabetic retinopathy research could reduce screening costs   Liver fat gets a wake-up call that maintains blood sugar levels   Low testosterone levels could raise diabetes risk for men   Prosthetic lets diabetic get a foot up on life   Dealing with Diabetes, One Patient at a Time

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]